ANAB - Company ID 0001370053
The table below shows ANAPTYSBIO, INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $234.60M | $91.28M | $17.16M | $10.29M | $63.17M | $75.00M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | $88.80M | $98.50M | $80.03M |
| SG&A |
ANAPTYSBIO, INC reported annual revenue of $234.60M for fiscal year 2025. That is up 157.0% from $91.28M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $16.68M (FY 2016) to $234.60M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $50.74M |
| $42.39M |
| $41.95M |
| $36.64M |
| $21.49M |
| $18.85M |
| Operating income | $47.90M | -$114.95M | -$164.41M | -$115.15M | -$56.81M | -$23.88M |
| Income tax | $164.00K | $3.00K | -$4.00K | $24.00K | $0.00 | $0.00 |
| Net income | -$13.23M | -$145.23M | -$163.62M | -$128.72M | -$57.80M | -$19.93M |
| EPS (diluted) | -$0.46 | -$5.12 | -$6.08 | -$4.57 | -$2.11 | -$0.73 |